Agentic AI Funding Shifts Toward Regulated, Workflow-Heavy Domains
Agentic AI funding refers to investment in artificial intelligence systems that act as autonomous agents performing end-to-end tasks inside business workflows, often across multiple software systems, instead of staying as passive assistants that only suggest actions to human operators.
The latest wave of agentic AI funding is not chasing another general-purpose chatbot; it is backing AI agents that shoulder real work in messy, regulated environments. Finto has raised USD 3.4 million (approx. RM15.6 million) to inject enterprise AI agents into accounting workflows, allowing software to perform the accounting itself rather than digitizing paperwork around it. Katalyze AI has secured USD 10.5 million (approx. RM48.1 million) in seed funding to expand an agentic operating system that sits on pharmaceutical plant floors and connects plant, lab, and enterprise data into a single operational record for scientists, engineers, analysts, and AI agents. Octozi has added USD 3 million (approx. RM13.8 million) in seed funding to automate clinical development workflows for pharmaceutical sponsors, focusing first on late-stage trials.
Taken together, these enterprise AI agents show where investors believe the next durable value will come from: not flashy demos, but deep workflow automation in industries that care less about novelty and more about audit trails, traceability, and outcomes measured in fewer manual hours and lower error rates.
Finto: Enterprise AI Agents That Do the Accounting Work
Accounting has long been a proving ground for automation, yet most tools stopped at digitization. Finto’s thesis is blunt: if finance teams are still touching most invoices by hand, the software is not intelligent enough. The company’s AI agents are designed to perform judgment-heavy accounting work directly—checking incoming invoices, assessing them for tax, coding them, matching them against purchase orders, resolving mismatches, and preparing postings into ERP systems. That is far beyond a workflow dashboard.
Backed by Y Combinator, Gradient, and Lightspeed, Finto’s USD 3.4 million round (approx. RM15.6 million) is a bet that agentic AI can turn accounting systems from passive record-keepers into active finance staffers. The platform integrates with ERP staples such as SAP, Microsoft Dynamics, and DATEV, and the company says the majority of invoices at its first customers now run without a manual human touch. In other words, this is not a copilot that drafts emails; it is an automated junior accountant working inside existing enterprise systems. If Finto is right, the future of enterprise AI agents looks less like chat windows and more like silent colleagues clearing queues in the background.
Katalyze AI: Pharma Manufacturing Automation Needs Agents, Not Dashboards
If accounting is difficult to automate, regulated pharma manufacturing is brutal. Operational data is scattered across manufacturing execution systems, laboratory information management systems, electronic lab notebooks, historians, SAP, and other enterprise applications that were never designed to behave as one record. Katalyze AI is attacking that problem by building an agentic AI operating system for pharmaceutical manufacturing and life sciences, and it has raised USD 10.5 million (approx. RM48.1 million) in seed funding to scale the effort.
The company connects plant, lab, quality, and enterprise data into a trusted operational layer that both humans and AI agents can use. Instead of generic chatbots, Katalyze emphasizes an operations-specific ontology and knowledge graph that give agents context for each process and molecule, so they can investigate production issues, support quality teams, and analyze manufacturing data while keeping every result linked back to source records. In one reported deployment, an analysis that could have taken roughly a year and cost between USD 4 million and USD 6 million (approx. RM18.3–27.4 million) was completed in 45 minutes. In pharma manufacturing automation, that level of traceable acceleration is not a convenience; it is the minimum bar for AI that touches GxP decisions.
Octozi: Clinical Development AI With Humans in the Loop
Clinical development is one of the most expensive and time-consuming processes in any industry, and its data operations layer has barely changed in decades. Trial data must be cleaned, reconciled, and reviewed before regulators will consider approving a new treatment, and much of that work still relies on data managers, medical monitors, and safety teams paging through records by hand. Octozi’s view is that this is precisely where agentic AI belongs—but only with tight human control.
The company, which automates clinical development workflows for pharmaceutical sponsors, has raised USD 3 million (approx. RM13.8 million) in seed funding to scale its platform. Octozi integrates with existing clinical systems and uses a human-in-the-loop design, combining large language models with deterministic clinical algorithms and external medical knowledge to accelerate data cleaning, reconciliation, review, and reporting for Phase III trials while keeping clinical teams in charge. In a controlled study, its AI support increased data cleaning throughput about six-fold, cut reviewer error rates from 54.7 percent to 8.5 percent, and reduced false positive queries about fifteen-fold, with an economic analysis estimating savings of more than USD 5 million (approx. RM22.8 million) per Phase III oncology trial. In clinical development AI, that kind of measured impact matters more than any novelty metric.
Why Vertical Agentic AI Wins Where Generic Copilots Fail
What unites Finto, Katalyze, and Octozi is not language models; it is the decision to build domain-specific agents that live directly inside regulated workflows. Their products are defined by data integration, human oversight, and traceability. Katalyze aims to turn fragmented manufacturing, lab, quality, and enterprise data into a single operational record that AI agents and experts can trust. Octozi plugs into clinical systems and keeps trial teams in the loop while accelerating data operations across thousands of patients in Phase III studies. Finto integrates with major ERP platforms so its accounting agents can act on real invoices, tax logic, and purchase orders rather than toy datasets.
The timing is no accident. Funding arrives as enterprise software providers push AI deeper into workflows around manufacturing, quality, supply chain, and finance. Much of the value in pharma manufacturing depends on connecting operational data across systems that were not designed for unified records; clinical development has similarly lagged in modern data operations. These startups are betting that the enduring opportunity in enterprise AI agents lies in the boring, regulated middle of the stack—where automation eliminates manual drudgery without sacrificing auditability.
The lesson for anyone building or buying AI is clear: in serious industries, the winners will not be the loudest copilots, but the quietest agents—the ones that disappear into existing systems, understand the domain in depth, and prove their worth with fewer errors, faster cycles, and clean data trails.
